Status:
COMPLETED
The Impact of Quetiapine on the Drug Abuse Patterns of Addicted Schizophrenic Patients
Lead Sponsor:
Université de Montréal
Collaborating Sponsors:
AstraZeneca
Conditions:
Schizophrenia
Substance Use Disorders
Eligibility:
All Genders
18-55 years
Phase:
PHASE4
Brief Summary
The lifetime of substance use disorders in schizophrenia is close to 50%. Substance abuse in schizophrenia is associated with negative consequences. Unfortunately, there no clear guidelines for the ph...
Eligibility Criteria
Inclusion
- Patients with as schizophrenia spectrum disorder
- Patients with a comorbid substance use disorder
Exclusion
- Patients already on quetiapine or clozapine
- Patients hospitalized or acutely ill
- Total score lower than 65 on the PANSS
- Pregnancy
- Female subjects of childbearing potential without adequate contraception
- Abnormal liver function (hepatic enzymes more than 3 times the upper normal limits)
- Any clinically meaningful unstable renal, hepatic, cardiovascular, respiratory, cerebrovascular disease or other serious, progressive physical disease.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00295412
Last Update
February 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de recherche Fernand-Seguin
Montreal, Quebec, Canada, H1N 3V2